Moreover, PASI 90 and PASI 100 scores were the highest for the head and neck region, indicating the highest response rates, while those for the lower extremities were consistently low at all visits.

Early response rates to these therapies were then examined for stable long-term response, as measured by associations with maintaining complete (PASI 100) or almost complete (PASI 90) skin ...

The emergence of new therapeutic classes for psoriasis has brought into focus the need to "set the bar higher" and adopt PASI 90 as the new standard for a good response, Pariser said. Rates of ...

Investigators enrolled 255 patients with a mean baseline PASI score of 19.1 and mean psoriasis duration ... PASI 100 response rates ranged from 10% to 40% across the JNJ-77242113 dose groups ...

It has recently been claimed that patients who achieve PASI scores less than or equal to 2 within the first 6 months of initiating biologic treatment tend to exhibit more stable psoriasis and a ...

PASI 100 rates at the same time points were 27% and 40% among patients switched from placebo to icotrokinra. IGA 0 response rate increased from 1% at 16 weeks to 23% at 24 weeks, and PASI 100 ...

The proportion of patients who achieved a PASI 100 score, signifying total clearance, approached 70% at 4 years in the group with the greatest response. PASI 90 and PASI 100 rates at this point ...

Other secondary endpoints included PASI 100 response and Investigator’s Global Assessment (IGA) scores of 0 and 1. At week 48, a greater proportion of guselkumab-treated patients achieved PASI ...

The co-primary end points were Psoriasis Area and Severity Index (PASI 90) response at week 16 and 52, defined as a patient that achieved a 90% reduction from baseline in the PASI score.

Sixteen weeks into the treatment regimen, 94% of the patients presented PASI 75 response, 76% PASI 90, and 39% were in complete remission (PASI 100). These results were similar in both study groups.

Although there was no statistically significant difference between the proportion of patients who achieved a PASI-50 response on EDP2939 compared to placebo, it was notable that such numeric ...